These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27181717)

  • 21. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.
    Nead KT; Sinha S; Nguyen PL
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):259-264. PubMed ID: 28349979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
    Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
    Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
    Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
    JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
    Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
    BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Crawley D; Adolfsson J; Rudman S; Van Hemelrijck M
    PLoS One; 2015; 10(3):e0117344. PubMed ID: 25794005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.
    Muniyan S; Xi L; Datta K; Das A; Teply BA; Batra SK; Kukreja RC
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188383. PubMed ID: 32535158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
    Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
    Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY; Lee JZ; Ha HK
    Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
    Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
    World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
    Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies.
    Scailteux LM; Naudet F; Alimi Q; Vincendeau S; Oger E
    Medicine (Baltimore); 2016 Jun; 95(24):e3873. PubMed ID: 27310974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
    Kassem L; Shohdy KS; Abdel-Rahman O
    Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
    Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
    J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis.
    Nead KT; Boldbaatar N; Yang DD; Sinha S; Nguyen PL
    Urology; 2018 Apr; 114():155-162. PubMed ID: 29352986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.